CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

When, where, and how to target vascular inflammation in the post-CANTOS era? Select Drug-Drug Interactions With Direct Oral Anticoagulants Same-Day Discharge After Elective Percutaneous Coronary Intervention: Insights From the British Cardiovascular Intervention Society Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Editorial2019 Aug 7;40(30):2492-2494.

JOURNAL:Eur Heart J. Article Link

When, where, and how to target vascular inflammation in the post-CANTOS era?

Maffia P, Guzik TJ. Keywords: atherosclerosis; target vascular inflammation; CANTOS trial; secondary prevention; history of myocardidal infarction; IL-1 pathway

LINK


This editorial refers to ‘Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis’, by A. Vrommanetal., doi:10.1093/eurheartj/ehz008